The projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals with pharma companies, a new analysis finds.
The projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals with pharma companies, a new analysis finds.
<iframe src="https://statesidedaily.com/embed/cluster/602bf2026c3e9c4be19589750f6e9c2ece416ead" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests"></iframe>